[Metastases from urothelial carcinoma : future and prospects].
Although bladder cancer is a chemosensitive tumor, results concerning metastatic lesions are poor. Nevertheless, Cisplatin-based chemotherapies are still the treatment of choice. Nowadays, the arrival of new active molecules especially anti-angiogenic drugs incites urooncologists to test their activity on urothelial carcinoma. Furthermore, the development of the concept of individualized treatment through identification of molecular prognostic factors and the application of targeted therapy have gained huge interest.
Lebret
T
T
Service d'Urologie, Hôpital Foch, Faculté de médecine Paris-Ile-de-France-Ouest, UVSQ, France. t.lebret@hopital-foch.org
Méjean
A
A
D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000556:secondary*; D005544:Forecasting; D006801:Humans; D001749:Urinary Bladder Neoplasms / Q000473:pathology*